Last reviewed · How we verify
Lipid microsphere
Lipid microspheres are colloidal lipid-based nanoparticles that encapsulate and deliver therapeutic agents or imaging contrast to target tissues.
Lipid microspheres are colloidal lipid-based nanoparticles designed to encapsulate and deliver drugs or imaging agents to target tissues. Used for Cancer therapy (specific indication not publicly detailed).
At a glance
| Generic name | Lipid microsphere |
|---|---|
| Also known as | Lipid microsphere injection |
| Sponsor | Peking University First Hospital |
| Drug class | Lipid nanoparticle delivery system |
| Modality | Small molecule |
| Therapeutic area | Oncology, Drug Delivery |
| Phase | FDA-approved |
Mechanism of action
Lipid microspheres function as drug delivery vehicles composed of lipid bilayers that can encapsulate hydrophobic or hydrophilic payloads. They circulate in the bloodstream and can passively accumulate in target tissues through the enhanced permeability and retention (EPR) effect, or be actively targeted via surface ligands. This platform technology enables improved bioavailability, reduced systemic toxicity, and enhanced therapeutic efficacy of encapsulated agents.
Approved indications
Common side effects
Key clinical trials
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy (EARLY_PHASE1)
- Phase II Trial of Lung Chemoemobolization (PHASE2)
- Lumason® Infusion vs. Bolus Administrations (PHASE3)
- CEUS Evaluation of Hydrocephalus in Neonates and Infants (PHASE2)
- Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer (PHASE2, PHASE3)
- Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors (PHASE2)
- Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation (PHASE2)
- Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipid microsphere CI brief — competitive landscape report
- Lipid microsphere updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI